Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors
- PMID: 34923623
- DOI: 10.1111/bjh.18001
Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors
Keywords: CML; COVID-19; SARS-CoV-2; TKI; vaccines.
References
REFERENCES
-
- Gupta S, Cantor J, Simon KI, Bento AI, Wing C, Whaley CM. Vaccinations against COVID-19 may have averted up to 140,000 deaths in the United States. Health Aff. 2021;40(9):1465-72.
-
- Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737-e45.
-
- Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165-73.
-
- Ghione P, Gu JJ, Attwood K, Torka P, Goel S, Sundaram S, et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies. Blood. 2021;138:811-4.
-
- Breccia M, Abruzzese E, Accurso V, Attolico I, Barulli S, Bergamaschi M, et al. COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. Br J Haematol. 2021. https://doi.org/10.1111/bjh.17890
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous